Comparison of guidelines for the management of hypertension: Similarities and differences between international and Asian countries; perspectives from HOPE-Asia Network

the Hypertension Cardiovascular Outcome Prevention, Evidence (HOPE) Asia Network

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Guidelines on the management of hypertension have been developed by various professional bodies and institutions to primarily address the issues of diagnosis, treatment, and control in order to rationalize and improve the management of hypertension. Hypertension guidelines across the world have recently been updated following the new and controversial lower blood pressure threshold of ≥130/80 mmHg for the diagnosis of hypertension adopted by the Americans. While there are differences between the major as well as between the Asian national guidelines, there were also many similarities. This paper discusses and highlights the differences and similarities between the major international guidelines of the American College of Cardiology/American Heart Association, of the European Society of Cardiology/European Society of Hypertension, and of the International Society of Hypertension and also compares them with the Asian guidelines.

Original languageEnglish
Pages (from-to)422-434
Number of pages13
JournalJournal of Clinical Hypertension
Volume23
Issue number3
DOIs
Publication statusPublished - 2021 Mar

Bibliographical note

Funding Information:
S Hoshide has received research grants from Sanofi Co., Astellas Pharma Inc and Novartis Pharma KK. KK has received independent principal investigator‐initiated research grants from Omron Healthcare Inc, Fukuda Denshi Inc, A&D Inc, Taisho Pharmaceutical Co. Inc, and Sanwa Kagaku Kenkyusho Co. Inc. YC Chia has received honorarium and sponsorship at attend conferences and seminars from Boeringher‐Ingelheim, Pfizer, Omron, Servier and Xepa‐Sol and an investigator‐initiated research grant from Pfizer. CH Chen reports personal fees from Novartis, Sanofi, Daiichi Sankyo, SERVIER, Bayer, and Boehringer Ingelheim Pharmaceuticals, Inc. HM Cheng received speaker honorarium and sponsorship to attend conferences and CME seminars from Eli Lilly and AstraZeneca; Pfizer Inc; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Novartis Pharmaceuticals, Inc; SERVIER; Co., Pharmaceuticals Corporation; Sanofi; TAKEDA Pharmaceuticals International and served as an advisor or consultant for ApoDx Technology, Inc. S Park reports research grant from Sankyo; lecture fee from Sankyo, Servier, Daewoong, Donga, Takeda, Boryung, Hanmi, Pfizer and Servier. All other authors report no potential conflicts of interest in relation to this review paper.

Publisher Copyright:
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Comparison of guidelines for the management of hypertension: Similarities and differences between international and Asian countries; perspectives from HOPE-Asia Network'. Together they form a unique fingerprint.

Cite this